Fig. 2

circFOXP1 promotes cell proliferation in vitro and in vivo. a Cell proliferation capacity was evaluated with CCK8 assays. Briefly, 2000 cells/well were plated in triplicate and cell proliferation was detected at days 1, 2, 3, 4, 5, 6 and 7 days after transfection of NOZ and SGC-996 cells (top) with sh-NC, sh-circFOXP1–1 or sh-circFOXP1–2 or of GBC-SD and EHGB-1 cells (low) with pLCDH-vector and pLCDH-circFOXP1. The experiment was repeated three times, **P < 0.01. b Data are presented as the percentage cell phase distribution including G0/G1, S and G2/M phases after transfection of NOZ and SGC-996 cells with sh-NC, sh-circFOXP1–1 or sh-circFOXP1–2 or GBC-SD cells with pLCDH-vector and pLCDH-circFOXP1, *P < 0.05; **P < 0.01. c The data are presented as cell apoptosis rates after transfection of NOZ and SGC-996 cells (left) with sh-NC, sh-circFOXP1–1 or sh-circFOXP1–2 or GBC-SD cells (right) with pLCDH-vector and pLCDH-circFOXP1. **P < 0.01. d Tumor weight and volume were detected to monitor tumor growth in subcutaneous implantation mouse models; mice were implanted with GBC-SD cells (top) transfected with pLCDH-vector or pLCDH-circFOXP1 and NOZ cells (low) transfected with lv-sh-NC, lv-sh-circFOXP1–1 or lv-sh-circFOXP1–2. e Immunohistochemical staining of Ki67 expression was shown in tumor tissues, as indicated by the number of Ki67-positive cells with GBC-SD cells (top) transfected with pLCDH-vector or pLCDH-circFOXP1 and NOZ cells (low) transfected with lv-sh-NC, lv-sh-circFOXP1–1 or lv-sh-circFOXP1–2, (original magnification, 200×)